Insider Buying: iBio, Inc. (NYSE:IBIO) Director Buys 18,382 Shares of Stock

iBio, Inc. (NYSE:IBIO) Director David Arkowitz purchased 18,382 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were acquired at an average price of $2.72 per share, with a total value of $49,999.04. Following the completion of the acquisition, the director now owns 18,382 shares in the company, valued at approximately $49,999.04. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

iBio Stock Down 2.7 %

Shares of iBio stock opened at $2.48 on Tuesday. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average price of $2.51 and a two-hundred day moving average price of $2.29. iBio, Inc. has a 1-year low of $1.02 and a 1-year high of $4.98.

iBio (NYSE:IBIO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.46) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.46). As a group, sell-side analysts expect that iBio, Inc. will post -1.74 earnings per share for the current year.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.